Navigation Links
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Date:5/22/2012

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., May 22, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar® (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.  An improvement in the secondary endpoint of progression-free survival (PFS) was observed.

The study compared Nexavar plus best supportive care to placebo plus best supportive care. The safety and tolerability data were generally as expected.  The data will be presented at an upcoming scientific meeting.

"While we are disappointed that the primary endpoint was not met, we believe the study results will advance the scientific knowledge in lung cancer," said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare.

Phase 3 Trial Design

The MISSION (Monotherapy admInistration of Sorafenib in patientS wIth nOn-small cell luNg cancer) trial is an international multicenter study that randomized 703 patients with advanced relapsed or refractory non-squamous NSCLC whose disease progressed after two or three previous treatments. Patients were randomized to receive either Nexavar as single agent or placebo. In both study arms, best supportive care was provided. The primary endpoint of the trial was overall survival, and secondary endpoints included progression-free survival, disease control rate, overall response rate, time to progression and quality of life.

The study was conducted at more than 150 sites in North America, South America, Europe, Africa and the Asia-Pacific region, inclu
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
2. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
3. Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
4. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
9. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
10. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... , Sept. 18, 2014  ADM Tronics ... DeNovi , Ph.D. to its corporate Advisory Board ... an instructor at the Harvard Medical School and ... Rome.  He received his Masters degree in Electronics ... Systems from the University of Bologna. After spending a ...
(Date:9/18/2014)... , Sept. 18, 2014  A $3 million grant ... the University of Michigan to establish a national center ... Glenn Center for Aging Research at U-M will focus ... can slow the effects of aging and postpone diseases ... aging that can help develop medications that may help ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3
(Date:9/18/2014)... temperatures in the Atlantic Ocean may be allowing certain ... becoming warmer, an expansion that could pose a significant ... of 40 species along the reefs off the North ... poisonous lionfish, according to researchers from the National Oceanic ... Carolina-Wilmington, who published their findings in the September issue ...
(Date:9/18/2014)... PITTSBURGH, PA (PRWEB) September 18, 2014 ... efficient patient care while also maintaining the patient's privacy," ... came up with this idea in order to supply ... jobs well." , They created a prototype for The ... The device enables staff to turn patient onto his ...
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 One ... the air medical transport industry, ShandsCair Flight Program’s ... Airbus Helicopters Inc . (AHI) at the Air Medical ... The recently delivered and placed into service ShandsCair EC155 ... that will be displayed at AMTC highlight Airbus Helicopters ...
(Date:9/18/2014)... Alan Mozes HealthDay ... When it comes to emergency room waiting times, patients seeking ... time staring down the clock than those seen at smaller ... of crowding and our ability to provide timely emergency care ... of the authors of the new research, Dr. Renee Hsia, ...
(Date:9/18/2014)... proven it true: exercise is good for you. But ... exercise may have an added benefit for cancer patients ... model of melanoma, found that combining exercise with chemotherapy ... Libonati, an associate professor in the School of Nursing ... Nursing Research, was the senior author on the study, ...
Breaking Medicine News(10 mins):Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2
... A new cafe called the Dana Cafe Light Lounge has ... overcoming the winter blues//. A dose of light is given ... produced by the dark winter days in the country. The ... in the country, which can result in depression. Most ...
... have to wait long before they were given treatment, which ... workers are seriously agitating against this issue and want doctors ... ,Though the trust feel that the actions of ... number of patients attending the hospitals during winter has been ...
... Norwich Union Healthcare reveals that the number of people claiming to ... magazines. The results were based on a survey of 250 general ... 250 GP’s; almost 167 of them said that they had seen ... 187 said that it was psychological. ,What they ...
... Health Minister Xavier Bertrand as said that the French government ... from a pandemic bird flu infection, the ministry has presented ... has a population of 62 million and the minister said ... and has ordered more than 40 million flu vaccines. The ...
... disgraced scientist from South Korea has formally apologized for ... your forgiveness," he said// in a televised press conference ... feel so miserable that it's difficult even to say ... University panel investigating Hwang concluded he had never cloned ...
... the prude university say that the long winter might make ... will keep away their winter blues//. ,Jane Kinyon, ... it is very common to suffer from mild irritation and ... sunlight and freezing temperatures. But this should not dampen one’s ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: